Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Neal Ready et al.|European Journal of Cancer|2018Cited by 267
909 Differentiation subgroups within LKB1-deficient lung cancer influence both the immune exclusion phenotype and cellular composition of the immune microenvironmentJacob M. Kaufman, Kris C. Wood, Doug Cress et al.|Regular and Young Investigator Award Abstracts|2021Cited by 1
Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.Jacob Kaufman, David P. Carbone, Dwight H. Owen et al.|Journal of Clinical Oncology|2023Cited by 1